양자 세포치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global adoptive cell therapy market size is expected to reach USD 37.07 Billion in 2034 from USD 13.09 Billion in 2025, growing at a CAGR of 12.26% during 2026-2034.This market is developing as pharmaceutical and biotechnology companies advance personalized cellular therapies designed to use immune cells to target specific diseases. Adoptive cell therapy involves collecting, modifying or expanding, and administering immune cells to patients, with applications particularly associated with oncology. CAR-T cell therapy has demonstrated the potential of engineered immune cells in selected blood cancers, encouraging further research into other cell-based approaches. Continued investment in cellular immunotherapy is supporting development across pharmaceutical companies, biotechnology firms, hospitals, and research institutions.

Research is increasingly focused on expanding adoptive cell therapy beyond established applications. Scientists are investigating T-cell receptor therapies, tumor-infiltrating lymphocytes, natural killer cells, and next-generation engineered immune cells. Developers are also working to improve cell persistence, target specificity, manufacturing consistency, and treatment accessibility. Advances in gene editing and cell engineering are providing additional tools for developing more sophisticated therapies. However, manufacturing complexity, treatment costs, patient eligibility, and clinical-management requirements remain important considerations for commercialization.

Future prospects depend on clinical development, manufacturing innovation, regulatory progress, and the ability to address limitations associated with current cell therapies. Automated manufacturing systems and improved cryopreservation could help increase production efficiency and consistency. Research into off-the-shelf or allogeneic cell therapies may also support broader access if technical and clinical challenges are addressed. The development of therapies targeting solid tumors and additional diseases could expand the market considerably. Continued collaboration between researchers, hospitals, and biotechnology companies is expected to drive innovation in cellular immunotherapy.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• CAR-T
• TCR-T
• NK
• TIL

By Application

• Lymphoma
• Leukemia
• Others

By End User

• Hospitals
• Cancer Treatment Centers

COMPANIES PROFILED

• Novartis AG, Gilead Sciences Inc., Castle Creek Biosciences Inc., Lineage Cell Therapeutics Inc., Transgene SA, Cellectis, ImmunityBio Inc., bluebird bio Inc., Arcellx Inc., Sana Biotechnology Inc., Biodesix Inc., Laurus Labs

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ADOPTIVE CELL THERAPY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. CAR-T Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. TCR-T Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. NK Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. TIL Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ADOPTIVE CELL THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ADOPTIVE CELL THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Treatment Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ADOPTIVE CELL THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By End User
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ADOPTIVE CELL THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis AG
  • 9.2.2 Gilead Sciences Inc
  • 9.2.3 Castle Creek Biosciences Inc
  • 9.2.4 Lineage Cell Therapeutics Inc
  • 9.2.5 Transgene SA
  • 9.2.6 Cellectis
  • 9.2.7 ImmunityBio Inc
  • 9.2.8 Bluebird Bio Inc
  • 9.2.9 Arcellx Inc
  • 9.2.10 Sana Biotechnology Inc
  • 9.2.11 Biodesix Inc
  • 9.2.12 Laurus Labs